Prostatype Genomics
0.027 SEK +8.16%3 investors are following this company
Prostatype Genomics is active in medical technology. The company specializes in the development of medical-technical genetic tests that are used for identification, analysis, and further follow-up of prostate cancer. In addition to the main business, service and associated ancillary services are also offered. The operations are found worldwide with the largest presence in the Nordic market.
Revenue
1.36M
EBIT %
-2,886.03 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
PROGEN
Daily low / high price
0.024 / 0.028
SEK
Market cap
26.26M SEK
Turnover
28.65K SEK
Volume
1.1M
Financial calendar
Extraordinary general meeting
2024-07-16
Interim report
2024-08-22
Annual report
2025-02-13
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Håkan Englund | 8.3 % | 8.3 % |
Johan Waldhe | 8.1 % | 8.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
NOTICE OF Extraordinary GENERAL MEETING IN Prostatype Genomics ab (PUBL)
Prostatype Genomics genomför en företrädesemission av units på cirka 49,5 MSEK
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools